NAFLD is strongly associated with obesity and metabolic disease. Obesity has clinical implications that extend beyond the liver. It is associated with insulin resistance which plays an important role in NASH. Agents with combined PPAR agonism may hold significant potential in this regard.

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In

6 + 2 =